|
Dec 20
|
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
|
|
Dec 19
|
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
|
|
Dec 18
|
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect?
|
|
Dec 10
|
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
|
|
Dec 1
|
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript
|
|
Nov 30
|
Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High?
|
|
Nov 27
|
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
|
|
Nov 6
|
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
|
|
May 1
|
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
|
|
Apr 25
|
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
|